QQ客服 官方微博 反馈留言

	XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer
	Cui, Chengxu; Shu, Chang; Yang, Yi; Liu, Junbao; Shi, Shuping; Shao, Zhujun; Wang, Nan; Yang, Ting; Hu, Songnian
	2014
卷号	8期号:4页码:1864-1872
关键词	FOLFIRI XELIRI UGT1A polymorphism haplotype
ISSN号	1792-1074
DOI	10.3892/ol.2014.2335
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6684826
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Cui, Chengxu,Shu, Chang,Yang, Yi,et al. XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer[J],2014,8(4):1864-1872.
APA	Cui, Chengxu.,Shu, Chang.,Yang, Yi.,Liu, Junbao.,Shi, Shuping.,...&Hu, Songnian.(2014).XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer.,8(4),1864-1872.
MLA	Cui, Chengxu,et al."XELIRI compared with FOLFIRI as a second-line treatment in patients with. metastatic colorectal cancer".8.4(2014):1864-1872.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。